Erika Hamilton, Chair, Executive Committee, Breast and Breast Program Lead at Sarah Cannon Research Institute, shared Nancy Lin‘s, Breast Cancer Specialist and Director of EMBRACE MBC Program at Dana-Farber Cancer Institute, post on X, adding:
“HER2CLIMB regimen showing activity in leptomeningeal disease with cape/tras/tucatinib for HER-2 and BCSM.”
Quoting Nancy Lin‘s post:
“There are so few trials which enroll patients with LMD. So glad to demonstrate benefit with the HER2CLIMB regimen including meaningful improvements in neuro deficits and quality of life.”
Other articles featuring Erika Hamilton and Nancy Lin on OncoDaily.